NeOnc Technologies Holdings Inc
Research NeOnc Technologies Holdings Inc (NTHI) on Bullrun: market cap USD 117.06M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNTHI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 117.06M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 8.82M
- Free cash flow-USD 6.99M
Valuation Snapshot
latest market cap is USD 117.06M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 39.99K | -USD 62.15M | -USD 20.86M | n/a | -3.2 | USD 58.73K | USD 6.31M | -USD 17.51M |
| FY2024 | USD 83.00K | -USD 11.90M | -USD 4.21M | n/a | -0.69 | USD 64.89K | USD 24.72K | -USD 5.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 117.06M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 157.35M | n/a | n/a | n/a |
About NeOnc Technologies Holdings Inc
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NeOnc Technologies Holdings Inc's market cap?
NeOnc Technologies Holdings Inc's market capitalization is USD 117.06M.
What does NeOnc Technologies Holdings Inc do?
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.